Jazz Pharmaceuticals EV/EBIT JAZZ

Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2012.

Today, Oct 23, 2026: 15.9×
10-year median: 17.3×
Against its 10-year history: 37th; percentile: 0 is its lowest day, 100 its highest
10-year range: 9.4× to 161×
Peer median: 54.6×

Jazz Pharmaceuticals' EV/EBIT is 15.9× as of Oct 23, 2026.

That is below its ten-year median of 17.3×, close to the middle of its last ten years.

Over that time it ranged from 9.4× in Mar 2020 to 161× in Jul 2022.

The median for 10 large drugmakers of a similar size is 54.6×.

EV/EBIT over time

median 17.3×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	15.9×	15.7×	30.9×
2025	30.6×	12.9×	31.5×
2024	15.8×	15.5×	19.3×
2023	17.5×	17.1×	34.6×
2022	34.7×	32.9×	161×
2021	41.4×	12.2×	43.7×
2020	15.7×	9.4×	15.7×
2019	12.1×	9.8×	13.7×
2018	12.8×	12.3×	20.9×
2017	14.7×	14.5×	18.8×
2016	14.6×	11.7×	18.1×
2015	16.5×	15.6×	28.5×
2014	27.1×	20.7×	31.4×
2013	22.2×	14.6×	22.3×
2012	19.2×	15.2×	24.2×

Against its peers

Companies in Drug Manufacturers - General nearest Jazz Pharmaceuticals' size, closest first, today.

Company	EV/EBIT
JAZZJazz Pharmaceuticals	15.9×
BMRNBiomarin Pharmaceutical	25.8×
CORTCorcept Therapeutics	n/m
PTGXProtagonist Therapeutics	140×
TGTXTG Therapeutics	62.2×
ALKSAlkermes plc.	69.6×
AMRXAmneal Pharmaceuticals	18.3×
LGNDLigand Pharmaceuticals	57.7×
KNSAKiniksa Pharmaceuticals International	54.6×
BIIBBiogen	26.3×
INDVIndivior Pharmaceuticals	7.8×
Peer median	54.6×

Where Jazz Pharmaceuticals ranks

What the EV/EBIT tells you

What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.

Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.

More on Jazz Pharmaceuticals

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.